ATE535254T1 - Behandlung von krebs mit dem anti-erbb2- antikörper rhumab 2c4 - Google Patents
Behandlung von krebs mit dem anti-erbb2- antikörper rhumab 2c4Info
- Publication number
- ATE535254T1 ATE535254T1 AT03755724T AT03755724T ATE535254T1 AT E535254 T1 ATE535254 T1 AT E535254T1 AT 03755724 T AT03755724 T AT 03755724T AT 03755724 T AT03755724 T AT 03755724T AT E535254 T1 ATE535254 T1 AT E535254T1
- Authority
- AT
- Austria
- Prior art keywords
- her2
- treating cancer
- erbb2 antibody
- antibody rhumab
- rhumab
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39629002P | 2002-07-15 | 2002-07-15 | |
US48004303P | 2003-06-20 | 2003-06-20 | |
PCT/US2003/021590 WO2004008099A2 (en) | 2002-07-15 | 2003-07-11 | METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE535254T1 true ATE535254T1 (de) | 2011-12-15 |
Family
ID=30118578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03755724T ATE535254T1 (de) | 2002-07-15 | 2003-07-11 | Behandlung von krebs mit dem anti-erbb2- antikörper rhumab 2c4 |
Country Status (21)
Country | Link |
---|---|
US (2) | US20040106161A1 (de) |
EP (2) | EP1585966B8 (de) |
JP (3) | JP5069843B2 (de) |
CN (2) | CN102295703A (de) |
AT (1) | ATE535254T1 (de) |
AU (2) | AU2003273218C1 (de) |
BR (1) | BR0312534A (de) |
CA (1) | CA2490758C (de) |
CY (2) | CY1112631T1 (de) |
DK (2) | DK1585966T3 (de) |
ES (2) | ES2392525T3 (de) |
HK (1) | HK1082687A1 (de) |
HU (1) | HUP0600340A3 (de) |
IL (2) | IL165952A (de) |
MX (1) | MXPA05000403A (de) |
NO (1) | NO337855B1 (de) |
NZ (1) | NZ537660A (de) |
PL (1) | PL214010B1 (de) |
PT (2) | PT2263691E (de) |
RU (2) | RU2338751C2 (de) |
WO (1) | WO2004008099A2 (de) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US7393823B1 (en) | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
US7625859B1 (en) * | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
KR20130056201A (ko) | 2000-05-19 | 2013-05-29 | 제넨테크, 인크. | ErbB 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
US20090111127A1 (en) * | 2002-05-21 | 2009-04-30 | Monogram Biosciences Inc. | Surface Receptor Complexes as Biomarkers |
US20040229294A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
US20040229380A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
BRPI0408928A (pt) * | 2003-04-01 | 2006-09-12 | Monogram Biosciences Inc | métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente |
US20100291594A1 (en) * | 2003-07-17 | 2010-11-18 | Laboratory Corporation Of America Holdings | ErbB Surface Receptor Complexes as Biomarkers |
US7402398B2 (en) * | 2003-07-17 | 2008-07-22 | Monogram Biosciences, Inc. | Measuring receptor homodimerization |
EP1673399B1 (de) * | 2003-08-11 | 2017-04-05 | Monogram BioSciences, Inc. | Nachweis und erstellung des profils eines molekularen komplexes |
EP1681983A4 (de) | 2003-10-14 | 2008-12-10 | Monogram Biosciences Inc | Rezeptor-tyrosin-kinase-signalpfad-analyse für diagnose und therapie |
US7329495B2 (en) | 2004-06-09 | 2008-02-12 | Board Of Regents, The University Of Texas System | Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors |
SV2006002143A (es) * | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
UA90480C2 (uk) * | 2004-07-22 | 2010-05-11 | Джэнэнтэк, Инк. | Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2 |
WO2006042002A2 (en) * | 2004-10-05 | 2006-04-20 | Oregon Health And Science University | Compositions and methods for treating disease |
CN101036055B (zh) * | 2004-10-06 | 2011-06-29 | 威尔斯达特生物制剂公司 | 循环癌细胞上Her-2/neu蛋白的增加水平的检测以及治疗 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2006045991A1 (en) * | 2004-10-25 | 2006-05-04 | Astrazeneca Ab | Method to predict whether a tumor will react to a chemotherapeutic treatment |
CA2587519A1 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
AU2005325200A1 (en) * | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of HER antibodies |
JP2008531576A (ja) * | 2005-02-23 | 2008-08-14 | ジェネンテック・インコーポレーテッド | Her二量体化阻害剤を使用した、ガン患者における疾患の進行までの期間または生存の延長 |
TW200642695A (en) * | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
US20070009976A1 (en) * | 2005-07-06 | 2007-01-11 | Helmut Lenz | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US7700299B2 (en) * | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
EP2008102A4 (de) * | 2006-04-18 | 2009-07-08 | Wellstat Biologics Corp | Detektion von proteinen aus zirkulierenden neoplastischen zellen |
MX2008013333A (es) * | 2006-04-18 | 2008-11-10 | Wellstat Biologics Corp | Deteccion de celulas endoteliales circulantes. |
CN101478998B (zh) * | 2006-06-27 | 2012-02-08 | 旭化成株式会社 | 生物学液体处理用基材 |
BRPI0717416A2 (pt) * | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
MX2009008909A (es) | 2007-03-01 | 2009-08-28 | Symphogen As | Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico. |
NZ578824A (en) | 2007-03-02 | 2012-03-30 | Genentech Inc | Predicting response to a her dimerisation inhibitor based on low her3 expression |
US20090304590A1 (en) * | 2007-05-29 | 2009-12-10 | Wyeth | Therapeutic compositions and methods |
US20090258005A1 (en) * | 2007-05-29 | 2009-10-15 | Trubion Pharmaceuticals Inc. | Therapeutic compositions and methods |
US20100298156A1 (en) | 2007-06-08 | 2010-11-25 | Si Tuen Lee-Hoeflich | Gene expression markers of tumor resistance to her2 inhibitor treatment |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
EP2179291B1 (de) * | 2007-07-13 | 2014-10-22 | Nestec S.A. | Arzneistoffauswahl für die lungenkrebstherapie unter verwendung von arrays auf antikörperbasis |
CA2705263A1 (en) * | 2007-11-09 | 2009-05-14 | Novartis Ag | Combination therapy with an antagonist anti-cd 40 antibody and cyclophosphamide, doxorubicin, vincristine and prednisone (chop) for treatment of b-cell malignancies |
EP2215123A1 (de) * | 2007-11-27 | 2010-08-11 | Ablynx N.V. | Immunglobulinkonstrukte |
US10416162B2 (en) | 2007-12-20 | 2019-09-17 | Monogram Biosciences, Inc. | Her2 diagnostic methods |
CN101932333A (zh) | 2007-12-26 | 2010-12-29 | 瓦西尼斯公司 | 抗c35抗体联合疗法和方法 |
US20140127200A1 (en) * | 2008-01-03 | 2014-05-08 | The Scripps Research Institute | Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
ES2553390T3 (es) * | 2008-02-25 | 2015-12-09 | Nestec S.A. | Método para la detección de receptores truncados intracelulares |
JP5800454B2 (ja) * | 2008-05-23 | 2015-10-28 | 株式会社ノエビア | 皮膚外用剤、経口剤、抗酸化剤、抗老化剤、及び免疫賦活剤 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
CA2729796C (en) | 2008-07-08 | 2017-07-04 | George Mason Intellectual Properties, Inc. | Phosphorylated c-erbb2 as a superior predictive theranostic marker for the diagnosis and treatment of cancer |
EA020855B1 (ru) * | 2008-08-05 | 2015-02-27 | Эй.Эл.Эм. ХОЛДИНГ КОМПАНИ | Способ холодного локального регенерирования, использующий вспененный асфальт и смазочную добавку |
MX2011001927A (es) | 2008-08-29 | 2011-04-21 | Symphogen As | Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico. |
CA2764386C (en) | 2008-12-01 | 2018-05-01 | Laboratory Corporation Of America Holdings | P95-her2 antibodies and uses thereof |
WO2010083463A1 (en) * | 2009-01-15 | 2010-07-22 | Laboratory Corporation Of America Holdings | Methods of determining patient response by measurement of her-2 expression |
CA2749846C (en) | 2009-01-15 | 2018-08-07 | Laboratory Corporation Of America Holdings | Methods of determining patient response by measurement of her-3 |
NZ594665A (en) | 2009-03-20 | 2013-08-30 | Genentech Inc | Bispecific anti-her antibodies |
WO2010132723A1 (en) * | 2009-05-14 | 2010-11-18 | Prometheus Laboratories Inc. | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
US20120121586A1 (en) | 2009-05-29 | 2012-05-17 | Astrid Kiermaier | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
JP5795311B2 (ja) | 2009-07-15 | 2015-10-14 | ネステク ソシエテ アノニム | 抗体ベースのアレイを使用する胃癌療法のための薬物選択 |
CN102892779B (zh) | 2010-02-18 | 2016-12-21 | 基因泰克公司 | 神经调节蛋白拮抗剂及其在治疗癌症中的用途 |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
US9155802B2 (en) * | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
US20130245233A1 (en) | 2010-11-24 | 2013-09-19 | Ming Lei | Multispecific Molecules |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
AU2012258637B2 (en) | 2011-05-24 | 2017-07-20 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
MX2014001766A (es) | 2011-08-17 | 2014-05-01 | Genentech Inc | Anticuerpos de neuregulina y sus usos. |
EP2751562B1 (de) | 2011-09-02 | 2015-09-16 | Nestec S.A. | Profilierung von signalwegproteinen zur bestimmung der therapeutischen wirksamkeit |
SG11201400150TA (en) | 2011-09-30 | 2014-03-28 | Regeneron Pharma | Anti-erbb3 antibodies and uses thereof |
US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
EP3974832A1 (de) * | 2011-10-06 | 2022-03-30 | Aveo Pharmaceuticals, Inc. | Vorhersage einer tumorreaktion auf anti-erbb3-antikörper |
PE20142363A1 (es) | 2011-10-14 | 2015-01-30 | Genentech Inc | Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
MX350957B (es) | 2011-11-23 | 2017-09-27 | Medimmune Llc | Moleculas de union especificas para her3 y usos de las mismas. |
RU2019103083A (ru) | 2011-11-30 | 2019-03-22 | Дженентек, Инк. | МУТАЦИИ ErbB3 ПРИ РАКЕ |
EP2788500A1 (de) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identifizierung von non-respondern auf her2-inhibitoren |
US20130259867A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
US9527913B2 (en) | 2012-05-02 | 2016-12-27 | Symphogen A/S | Humanized pan-HER antibody compositions |
TWI641619B (zh) * | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | 抗-egfr抗體及其用途 |
JP2015532306A (ja) | 2012-10-15 | 2015-11-09 | チューリッヒ大学 | 癌治療のための二重特異性her2リガンド |
EP2719706A1 (de) | 2012-10-15 | 2014-04-16 | Universität Zürich | Bispezifische HER2-Liganden zur Krebstherapie |
WO2014083178A1 (en) | 2012-11-30 | 2014-06-05 | F. Hoffmann-La Roche Ag | Identification of patients in need of pd-l1 inhibitor cotherapy |
EP2968541A4 (de) | 2013-03-15 | 2017-02-08 | Zyngenia, Inc. | Multivalente und monovalente multispezifische komplexe und deren verwendungen |
EP2981828A1 (de) * | 2013-04-05 | 2016-02-10 | Laboratory Corporation of America Holdings | Systeme und verfahren zur erleichterung der diagnose, prognose und behandlung von krebs auf basis der erkennung einer her3-aktivierung |
AU2014254086B2 (en) * | 2013-04-16 | 2018-07-05 | Genentech, Inc. | Pertuzumab variants and evaluation thereof |
US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
EP3087394A2 (de) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarkerprofile zur vorhersage der ergebnisse einer krebstherapie mit erbb3-inhibitoren und/oder chemotherapien |
US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
EP3581586A1 (de) | 2014-04-25 | 2019-12-18 | F. Hoffmann-La Roche AG | Verfahren zur behandlung von frühzeitigem brustkrebs mit trastuzumab-mcc-dm1 und pertuzumab |
CN105985435B (zh) | 2015-01-30 | 2019-10-15 | 嘉和生物药业有限公司 | 全人源her2抗体的突变抗体及其编码基因和应用 |
CN107614015A (zh) | 2015-05-30 | 2018-01-19 | 豪夫迈·罗氏有限公司 | 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法 |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
EP3418744A4 (de) * | 2016-02-19 | 2018-12-26 | Konica Minolta, Inc. | Durch quantitative beurteilung von versuchstierproben charakterisiertes nicht-klinisches prüfverfahren |
EP3454863A1 (de) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Kombinationstherapien zur behandlung von krebs |
US10377833B2 (en) | 2016-07-22 | 2019-08-13 | Beijing Mabworks Biotech Co., Ltd. | Bispecific anti-HER2 antibody |
CN107446045A (zh) | 2016-07-22 | 2017-12-08 | 北京天广实生物技术股份有限公司 | 一种抗her2的抗体、其药物组合物及用途 |
AU2017355432A1 (en) | 2016-11-04 | 2019-05-16 | F. Hoffmann-La Roche Ag | Treatment of HER2-positive breast cancer |
CA3046092A1 (en) | 2016-12-28 | 2018-07-05 | Genentech, Inc. | Treatment of advanced her2 expressing cancer |
DK3570884T3 (da) | 2017-01-17 | 2020-11-30 | Genentech Inc | Subkutane HER2-antistofformuleringer |
CN116850283A (zh) | 2017-03-02 | 2023-10-10 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
EP3615695A1 (de) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2-mutationen in der transmembran- oder juxtamembran-domäne |
WO2019241599A1 (en) * | 2018-06-14 | 2019-12-19 | Memorial Sloan Kettering Cancer Center | Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies |
EP3826635A4 (de) | 2018-07-23 | 2022-04-27 | Trevi Therapeutics, Inc. | Behandlung von chronischem husten, kurzatmigkeit und dyspnoe |
BR112021003472A2 (pt) | 2018-09-06 | 2021-05-18 | Daiichi Sankyo Company, Limited | derivado de dinucleotídeo cíclico e conjugado de anticorpo-fármaco do mesmo |
CA3113306A1 (en) | 2018-10-08 | 2020-04-16 | Universitat Zurich | Her2-binding tetrameric polypeptides |
WO2021188578A1 (en) * | 2020-03-16 | 2021-09-23 | University Of Southern California | Screening methods to identify small molecule compounds that promote or inhibit the growth of circulating tumor cells, and uses thereof |
TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體-免疫賦活化劑共軛物之新穎製造方法 |
BR112023017365A2 (pt) | 2021-03-12 | 2023-10-03 | Daiichi Sankyo Co Ltd | Glicano e método para produzir medicamento contendo glicano |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US197835A (en) * | 1877-12-04 | Improvement in dovetailing and grooving machines | ||
US229380A (en) * | 1880-06-29 | John charles | ||
US126818A (en) * | 1872-05-14 | Improvement in carpet-stretchers | ||
US229293A (en) * | 1880-06-29 | Swinging can | ||
US229294A (en) * | 1880-06-29 | woolnoug-h | ||
US190689A (en) * | 1877-05-15 | Improvement in car-brakes | ||
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4474683A (en) | 1981-08-10 | 1984-10-02 | Armour-Dial, Inc. | Soap making process |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4933294A (en) | 1984-01-30 | 1990-06-12 | Icrf Patents Limited | Method of detecting truncated epidermal growth factor receptors |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (de) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformationsvektoren für Hefe Yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
ATE135373T1 (de) | 1989-09-08 | 1996-03-15 | Univ Johns Hopkins | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
WO1991005264A1 (en) | 1989-09-29 | 1991-04-18 | Oncogenetics Partners | Detection and quantification of neu related proteins in the biological fluids of humans |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
EP1400536A1 (de) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Verfahren zur Herstellung humanisierter Antikörper |
US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
DE69333082T2 (de) | 1992-02-11 | 2004-05-06 | Cell Genesys, Inc., Foster City | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
EP0655924A4 (de) | 1992-06-30 | 1996-09-11 | Oncologix Inc | EINE KOMBINATION VON MONOKLONALEN ANTIKÖRPERN GEGEN erbB-2 UND VERFAHREN ZUR IHRER NUTZUNG. |
AU668423B2 (en) | 1992-08-17 | 1996-05-02 | Genentech Inc. | Bispecific immunoadhesins |
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
US5811098A (en) * | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
CA2103323A1 (en) | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
DK0616812T3 (da) | 1993-03-24 | 2000-04-25 | Berlex Biosciences | Kombination af antihormonforbindelser og bindingsmolekyler til behandling af cancer |
WO1994022478A1 (en) | 1993-03-30 | 1994-10-13 | The Trustees Of The University Of Pennsylvania | PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU) |
DK0730740T3 (da) | 1993-11-23 | 1998-09-28 | Genentech Inc | Kinasereceptoraktiveringsassay |
AU697142B2 (en) | 1993-11-23 | 1998-10-01 | Genentech Inc. | Protein tyrosine kinases named Rse |
US6287784B1 (en) | 1993-11-23 | 2001-09-11 | Genentech, Inc. | Kinase receptor activation assay |
ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
JPH08510922A (ja) | 1994-03-17 | 1996-11-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 抗EGFR一本鎖Fvおよび抗EGFR抗体 |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
PL179659B1 (pl) | 1994-07-21 | 2000-10-31 | Akzo Nobel Nv | Kompozycja cyklicznych nadtlenków ketonów sluzaca do modyfikowania (ko)polimerów zwlaszcza do degradacji polipropylenu PL PL PL PL PL PL PL |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
WO1996016673A1 (en) | 1994-12-02 | 1996-06-06 | Chiron Corporation | Method of promoting an immune response with a bispecific antibody |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
DK0817775T3 (da) | 1995-03-30 | 2001-11-19 | Pfizer | Quinazolinderivater |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
CA2245835A1 (en) | 1995-06-14 | 1997-01-03 | The Regents Of The University Of California | Novel high affinity human antibodies to tumor antigens |
PT1516628E (pt) | 1995-07-27 | 2013-09-24 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
CA2246429C (en) | 1996-03-27 | 2007-07-24 | Genentech, Inc. | Erbb3 antibodies |
US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
CZ295468B6 (cs) | 1996-04-12 | 2005-08-17 | Warner-Lambert Company | Polycyklické sloučeniny |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
AU9805398A (en) | 1997-10-15 | 1999-05-03 | Children's Medical Center Corporation | Novel human egf receptors and use thereof |
BR9907852A (pt) * | 1998-02-12 | 2000-10-24 | Immunivest Corp | Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes |
US6417168B1 (en) * | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
US6514700B1 (en) | 1999-04-30 | 2003-02-04 | Aclara Biosciences, Inc. | Nucleic acid detection using degradation of a tagged sequence |
US6322980B1 (en) | 1999-04-30 | 2001-11-27 | Aclara Biosciences, Inc. | Single nucleotide detection using degradation of a fluorescent sequence |
US6627400B1 (en) * | 1999-04-30 | 2003-09-30 | Aclara Biosciences, Inc. | Multiplexed measurement of membrane protein populations |
AU5003200A (en) | 1999-05-14 | 2000-12-05 | United States Of America As Represented By The Department Of Veterans Affairs, The | Isolation and characterization of epidermal growth factor related protein |
US7049410B2 (en) | 1999-05-14 | 2006-05-23 | Majumdar Adhip P N | Antibodies to a novel EGF-receptor related protein (ERRP) |
CA2370466C (en) * | 1999-06-25 | 2011-02-08 | Sharon Erickson | Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
GEP20104998B (en) * | 1999-06-25 | 2010-06-10 | Genentech Inc | Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer |
US7041292B1 (en) * | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
ATE373017T1 (de) * | 1999-07-30 | 2007-09-15 | Medarex Inc | Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen |
US6627196B1 (en) * | 1999-08-27 | 2003-09-30 | Genentech, Inc. | Dosages for treatment with anti-ErbB2 antibodies |
KR20130056201A (ko) | 2000-05-19 | 2013-05-29 | 제넨테크, 인크. | ErbB 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
US20020119148A1 (en) | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
WO2002087619A1 (fr) * | 2001-04-27 | 2002-11-07 | Takeda Chemical Industries, Ltd. | Methode de prevention et de traitement du cancer |
JP2004002211A (ja) * | 2001-04-27 | 2004-01-08 | Takeda Chem Ind Ltd | 癌の予防・治療方法 |
US20030190689A1 (en) * | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
US20040229294A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
US20040229293A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | Surface receptor complexes as biomarkers |
US20040229380A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
AU2003251597A1 (en) * | 2002-06-19 | 2004-01-06 | Abgenix, Inc. | Method for predicting response to epidermal growth factor receptor-directed therapy |
WO2004011900A2 (en) * | 2002-07-25 | 2004-02-05 | Aclara Biosciences, Inc. | Detecting receptor oligomerization |
AU2005325200A1 (en) * | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of HER antibodies |
-
2003
- 2003-07-11 CN CN2011102788307A patent/CN102295703A/zh active Pending
- 2003-07-11 PT PT10176072T patent/PT2263691E/pt unknown
- 2003-07-11 HU HU0600340A patent/HUP0600340A3/hu unknown
- 2003-07-11 ES ES10176072T patent/ES2392525T3/es not_active Expired - Lifetime
- 2003-07-11 EP EP03755724A patent/EP1585966B8/de not_active Expired - Lifetime
- 2003-07-11 WO PCT/US2003/021590 patent/WO2004008099A2/en active Search and Examination
- 2003-07-11 MX MXPA05000403A patent/MXPA05000403A/es active IP Right Grant
- 2003-07-11 AT AT03755724T patent/ATE535254T1/de active
- 2003-07-11 ES ES03755724T patent/ES2376165T3/es not_active Expired - Lifetime
- 2003-07-11 CN CN200910207004A patent/CN101711866A/zh active Pending
- 2003-07-11 PT PT03755724T patent/PT1585966E/pt unknown
- 2003-07-11 PL PL377743A patent/PL214010B1/pl unknown
- 2003-07-11 DK DK03755724.6T patent/DK1585966T3/da active
- 2003-07-11 BR BRPI0312534-3A patent/BR0312534A/pt not_active Application Discontinuation
- 2003-07-11 CA CA2490758A patent/CA2490758C/en not_active Expired - Lifetime
- 2003-07-11 DK DK10176072.6T patent/DK2263691T3/da active
- 2003-07-11 RU RU2005103824/13A patent/RU2338751C2/ru active
- 2003-07-11 AU AU2003273218A patent/AU2003273218C1/en not_active Expired
- 2003-07-11 EP EP10176072A patent/EP2263691B1/de not_active Expired - Lifetime
- 2003-07-11 NZ NZ537660A patent/NZ537660A/en not_active IP Right Cessation
- 2003-07-11 JP JP2004521625A patent/JP5069843B2/ja not_active Expired - Lifetime
- 2003-07-14 US US10/619,754 patent/US20040106161A1/en not_active Abandoned
-
2004
- 2004-12-23 IL IL165952A patent/IL165952A/en active IP Right Grant
-
2005
- 2005-02-14 NO NO20050775A patent/NO337855B1/no not_active IP Right Cessation
-
2006
- 2006-04-19 HK HK06104646.4A patent/HK1082687A1/xx not_active IP Right Cessation
-
2008
- 2008-07-10 RU RU2008128244/13A patent/RU2008128244A/ru not_active Application Discontinuation
-
2010
- 2010-02-25 AU AU2010200692A patent/AU2010200692A1/en not_active Abandoned
- 2010-11-29 US US12/955,727 patent/US20110117096A1/en not_active Abandoned
-
2012
- 2012-02-17 CY CY20121100167T patent/CY1112631T1/el unknown
- 2012-04-24 IL IL219381A patent/IL219381A/en active IP Right Grant
- 2012-06-28 JP JP2012145330A patent/JP5678005B2/ja not_active Expired - Lifetime
- 2012-10-29 CY CY20121101025T patent/CY1113260T1/el unknown
-
2014
- 2014-07-14 JP JP2014144190A patent/JP2014237667A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE535254T1 (de) | Behandlung von krebs mit dem anti-erbb2- antikörper rhumab 2c4 | |
MA30654B1 (fr) | Therapie tumorale avec anticorps anti-vegf | |
IL254264A (en) | Doses for treatments using anti-erbb2 antibodies | |
PT991421E (pt) | Deteccao e modulacao das iap e naip para o diagnostico e tratamento de doenca proliferativa | |
DK1565489T3 (da) | Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet | |
NZ508456A (en) | FAP alpha-specific antibody with frame-work modifications resulting in improved producibility | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
TR200103756T2 (tr) | Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi. | |
BRPI0613382A8 (pt) | anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor | |
DE69738868D1 (de) | Odieren, und deren verwendung zur vorbeugung und zum nachweis von krebs | |
WO2005080431A3 (en) | Monoclonal antibodies that specifically bind to folate receptor alpha | |
RU2007125644A (ru) | Отбор пациентов для терапии ингибитором her | |
NO20045645L (no) | Noytraliserende humant anti-IGFR-antistoff | |
DE69927262D1 (de) | Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren | |
DE69131255D1 (de) | Immunreaktivität gegenüber exprimierten aktivierten Oncogenen zur Diagnose und Behandlung von bösartigen Geschwülsten | |
ATE495751T1 (de) | Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper | |
DE69229394T2 (de) | Zusammensetzungen und methoden zur behandlung von kleinzell und nicht-kleinzell lungenkrebsen |